Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
← catalyst calendarNCT04959448 · readout in 218 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
717actual
Sites
81
Countries
Canada, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-12 | actual | When the study began enrolling |
| Primary completion | 2027-03-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-25 | estimated | The whole study's end, after follow-up |
| First posted | 2021-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Rhinosinusitis With Nasal Polyposis
Intervention
- Drug: DUPIXENT® — also filed as dupilumab, REGN668, SAR231893
Primary outcomes
what the primary-completion date above is the date OFBaseline Patient Characteristics
measured Baseline up to 3 years
Baseline Disease Characteristics
measured Baseline up to 3 years
Publications
- PMID 40958188 — linked by the registry
- PMID 36451848 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed